Evidence map›Paper›PMID 42223872›Full record

ArticleAnnals of nuclear medicine2026

Local aggressiveness and prognostic prediction in desmoid-type fibromatosis: insights from

Yan Cui, Min Wang, Yitong Liu, Yang Liu, Yufei Song, Shizhen Zhai, Nan Li

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yan CuiKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Peking University Cancer Hospital & Institute, No. 52 Fucheng Rd, Beijing, 100142, China.
Min WangKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Peking University Cancer Hospital & Institute, No. 52 Fucheng Rd, Beijing, 100142, China.
Yitong LiuKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Peking University Cancer Hospital & Institute, No. 52 Fucheng Rd, Beijing, 100142, China.
Yang LiuKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Peking University Cancer Hospital & Institute, No. 52 Fucheng Rd, Beijing, 100142, China.
Yufei SongKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Peking University Cancer Hospital & Institute, No. 52 Fucheng Rd, Beijing, 100142, China.
Shizhen ZhaiKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Peking University Cancer Hospital & Institute, No. 52 Fucheng Rd, Beijing, 100142, China.
Nan LiKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Peking University Cancer Hospital & Institute, No. 52 Fucheng Rd, Beijing, 100142, China. rainbow6283@sina.com.ORCID http://orcid.org/0000-0001-8619-7550

Funding

Beijing Hospitals Authority's Ascent Plan DFL20241103Beijing Research Ward Excellence Program BRWEP2024W032150102National Key R&D Program of China 2022YFC2409405National Natural Science Foundation of China 82472015
6 · The paper itself

Abstract

objectiveTo investigate the value of

methodsWe retrospectively analyzed

resultsFifty-five lesions from 44 participants were included. ¹⁸F-FDG PET/CT showed higher accuracy and sensitivity than CE-MRI for assessing peritumoral invasion, with no statistically significant differences in paired comparisons. Notably, pathology in one case demonstrated tumor invasion of the lymph node capsules. Furthermore, DF lesions with PD or POR had significantly higher maximum standardized uptake value (SUV

conclusion

Indexed as

Desmoid TumorsFluorodeoxyglucose F18Positron Emission Tomography Computed TomographyAdolescentAdultAgedChildFemaleHumansMaleMiddle AgedNeoplasm InvasivenessPrognosisRetrospective StudiesYoung AdultFluorodeoxyglucose F1818F-FDG PET/CTContrast-enhanced MRIDesmoid-type fibromatosisPrognostic prediction

Identifiers

PMID42223872

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.